Revvity Inc
WHO'M
ai
Digital Profiler. Einfach den AI-Button klicken
FIGI: BBG000FP1JN9
RVTY
Revvity Inc
GICS: 35203010
·
Sektor: Healthcare
·
Sub-Sektor: Diagnostics & Research
NAME
Revvity Inc
ISIN
US7140461093
TICKER
RVTY
MIC
XNYS
REUTERS
RVTY.N
BLOOMBERG
RVTY US
F&G:
63
Financial Intelligence
FÜR INVESTOREN
FÜR TRADER
Der X-News Explorer ist die ultimative Informationsquelle für börsenaffine Anleger, die sich schnell und komfortabel einen Überblick über die aktuelle Nachrichtenlage eines börsennotierten Unternehmens verschaffen möchten. Ihnen stehen hier verschiedene Newswire-Services zur Verfügung. Wird ein News-Alert angezeigt, liegen Unternehmensnachrichten vor, die Sie möglicherweise interessieren könnten. Dieser Service wird Ihnen von BusinessWire bereitgestellt.
Mo., 02.06.2025
Revvity
US7140461093
Revvity, Inc. (NYSE: RVTY), today announced the launch of three Mimix™ reference standards for IVD use, designed for monitoring of next-generation sequencing (NGS) or droplet digital polymerase chain reacting (ddPCR) assays designed to detect somatic mutations in genomic DNA (gDNA) from human samples for IVD use. These cell line-derived reference ...
Mi., 02.04.2025
Revvity
US7140461093
Revvity, Inc. (NYSE: RVTY), today announced that the U.S. Food and Drug Administration (FDA) has approved the Auto-Pure 2400 liquid handling platform with the T-SPOT™.TB test. Initially launched outside the U.S. in 2024, this powerful combination allows laboratories to improve productivity while maintaining superior clinical performance in latent ...
Mo., 03.03.2025
Revvity
US7140461093
Revvity, Inc. (NYSE: RVTY), today announced the launch of EUROIMMUN’s CE-marked Anti-Measles Virus ELISA 2.0 (IgG) to support the diagnosis of a measles virus infection or to determine the immune status against measles virus. EUROIMMUN’s Anti-Measles Virus ELISA 2.0 (IgG) is the first of several assays in development expanding EUROIMMUN’s serologi...
Do., 20.02.2025
Revvity
US7140461093
Today, Revvity, Inc. (NYSE: RVTY) announced that the Massachusetts Superior Court has ruled in its favor and will issue a permanent injunction to enforce Revvity’s rights under its agreements with Cloud Software Group (CSG) related to the Spotfire® software.
This ruling follows a preliminary injunction issued in April 2024, which will become perm...
Do., 20.02.2025
Revvity
US7140461093
Revvity, Inc. (NYSE: RVTY), today announced it will present at the following investor conferences in March 2025:
46th Annual Raymond James Institutional Investor Conference
Monday, March 3, 2025
7:30 a.m. ET - Max Krakowiak, senior vice president and chief financial officer
TD Cowen 45th Annual Health Care Conference
Tuesday, March 4, 2025
9:10 ...
Fr., 31.01.2025
Revvity
US7140461093
Revvity, Inc. (NYSE: RVTY) today reported financial results for the fourth quarter and full year ended December 29, 2024.
Fourth Quarter 2024
The Company reported GAAP earnings per share of $0.78, as compared to $0.64 in the same period a year ago. GAAP revenue for the quarter was $729 million, as compared to $696 million in the same period a ...
Do., 23.01.2025
Revvity
US7140461093
The Board of Directors of Revvity (NYSE: RVTY), today declared a regular quarterly dividend of $0.07 per share of common stock. This dividend is payable on May 9, 2025 to all shareholders of record at the close of business on April 18, 2025.
About Revvity
At Revvity, “impossible” is inspiration, and “can’t be done” is a call to action. Revvity...
Mo., 13.01.2025
Revvity
US7140461093
Revvity, Inc. (NYSE: RVTY), today announced a strategic agreement to commercialize an in vitro diagnostic (IVD) workflow solution for neonatal sequencing, co-developed with Element Biosciences, Inc., a life science company democratizing access to advanced DNA and multi-omic sequencing solutions. This initiative builds upon Revvity's recent introdu...
Fr., 10.01.2025
Revvity
US7140461093
Revvity, Inc. (NYSE: RVTY), today announced that it received 510(k) clearance from the U.S. Food and Drug Administration (FDA) for EUROIMMUN’s automated chemiluminescence-based immunoassay (ChLIA) test for free testosterone. This innovative test is the first of its kind to receive FDA clearance for direct quantitative measurement of free testoster...
Di., 17.12.2024
Revvity
US7140461093
Revvity, Inc. (NYSE: RVTY) will present at the 43rd annual J.P. Morgan Healthcare Conference on Monday, January 13, 2025 at 8:15 a.m. PT in San Francisco, CA.
President and Chief Executive Officer Prahlad Singh will provide an update on the Company and its strategic priorities.
To access the presentation, a live audio webcast will be available...
Informationen zu Product Placements
BARRISTA SMART * AD
P R O D U C T S U G G E S T I O N S
